Edition:
India

Lupin Ltd (LUPN.NS)

LUPN.NS on National Stock Exchange of India

759.60INR
2:21pm IST
Change (% chg)

Rs5.40 (+0.72%)
Prev Close
Rs754.20
Open
Rs753.90
Day's High
Rs765.80
Day's Low
Rs753.00
Volume
1,408,660
Avg. Vol
1,857,991
52-wk High
Rs986.10
52-wk Low
Rs723.65

Latest Key Developments (Source: Significant Developments)

Lupin Gets USFDA Approval For Atorvastatin Calcium Tablets Usp
Thursday, 7 Mar 2019 

March 7 (Reuters) - Lupin Ltd ::SAYS LUPIN RECEIVES FDA APPROVAL FOR ATORVASTATIN CALCIUM TABLETS USP.SAYS DRUG INDICATED TO LOWER CHOLESTEROL IN BLOOD FOR ADULTS AND CHILDREN OVER 10 YEARS OF AGE.  Full Article

Lupin Says In Alliance With Natco Gets FDA Approval For Imatinib Mesylate Tablets
Tuesday, 5 Mar 2019 

March 5 (Reuters) - Lupin Ltd ::LUPIN - IN ALLIANCE WITH NATCO RECEIVES FDA APPROVAL FOR IMATINIB MESYLATE TABLETS.  Full Article

India's Lupin Launches Ranolazine Er Tablets In U.S
Thursday, 28 Feb 2019 

Feb 28 (Reuters) - Lupin Ltd ::SAYS LAUNCHES GENERIC RANOLAZINE ER TABLETS IN U.S..SAYS RANOLAZINE IS INDICATED FOR THE TREATMENT OF CHRONIC ANGINA.  Full Article

Lupin Launches Generic Minocycline Hydrochloride ER Tablets USP
Tuesday, 26 Feb 2019 

Feb 26 (Reuters) - Lupin Ltd ::SAYS CO LAUNCHES GENERIC MINOCYCLINE HYDROCHLORIDE ER TABLETS USP.  Full Article

Lupin Ltd Gets FDA Approval For Methylprednisolone Tablets USP
Monday, 25 Feb 2019 

Feb 25 (Reuters) - Lupin Ltd ::GETS FDA APPROVAL FOR METHYLPREDNISOLONE TABLETS USP.  Full Article

Lupin Gets USFDA Approval For Fluoxetine Tablets USP
Tuesday, 12 Feb 2019 

Feb 12 (Reuters) - Lupin Ltd ::SAYS LUPIN RECEIVES FDA APPROVAL FOR FLUOXETINE TABLETS USP.SAYS DRUG INDICATED FOR TREATMENT OF MAJOR DEPRESSIVE DISORDER, OBSESSIVE COMPULSIVE DISORDER, BULIMIA NERVOSA AND PANIC DISORDER.  Full Article

India's Lupin Gets FDA Approval For Tadalafil Tablets
Thursday, 7 Feb 2019 

Feb 7 (Reuters) - Lupin Ltd ::SAYS RECEIVES FDA APPROVAL FOR TADALAFIL TABLETS USP, 20 MG..  Full Article

Lupin Says Co Now Starting To See Growth In The U.S.
Wednesday, 6 Feb 2019 

Feb 6 (Reuters) - Lupin Ltd ::SAYS CO NOW STARTING TO SEE GROWTH IN THE U.S..GROWTH MOMENTUM IN THE U.S. WILL CONTINUE INTO NEXT QUARTER AS CO ON TRACK WITH LAUNCHES LIKE LEVOTHYROXINE AND RANOLAZINE.  Full Article

Lupin Launches Clomipramine Hydrochloride Capsules USP
Tuesday, 5 Feb 2019 

Feb 5 (Reuters) - Lupin Ltd ::LUPIN LAUNCHES CLOMIPRAMINE HYDROCHLORIDE CAPSULES USP.  Full Article

Lupin Launches Orphan Drug Namuscla In Germany And UK
Friday, 1 Feb 2019 

Feb 1 (Reuters) - Lupin Ltd ::SAYS LAUNCH OF ORPHAN DRUG NAMUSCLA IN GERMANY AND UK.  Full Article

RPT-ICRA ratings for Indian debt instruments-Feb 26

(Repeating to add more ratings.) Feb 26 Below are the ratings awarded by Investment Information Credit Rating Agency Ltd. (ICRA) for local debt instruments as of February 25, 2019. COMPANY INSTRUMENT RATING AMOUNT MOVEMENT (RS.MLN) ------ ---------- ------ ----- --------- SHORT TERM RATINGS: -------------